Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novavax, Inc. , a global company advancing protein-based vaccines with its Matrix-Mtm adjuvant, today announced that Åsa Manelius, will join the Company in February 2025 as Managing Director of the ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

In the most recent trading session, Novavax (NVAX) closed at $10.07, indicating a -1.76% shift from the previous trading day.

On Friday, Novavax Inc (NVAX) stock saw a decline, ending the day at $9.74 which represents a decrease of $-0.18 or -1.81% from the prior close of $9.92. The stock opened at $9.9 and touched a low of ...

As of 21 October at 3:10 pm GMT-4. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

Vaccine maker Novavax (NASDAQ: NVAX) has had a rollercoaster of a year. In May, the company's shares soared after it announced a lucrative agreement with biotech giant Sanofi. It's been mostly ...

Novavax's planned phase 3 clinical trials just hit a roadblock. The stock didn't look that attractive before this development. This setback adds more uncertainty to Novavax's prospects. However ...

Vaccine maker Novavax (NASDAQ: NVAX) has had a rollercoaster of a year. In May, the company's shares soared after it ...

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...